Related Experiment Video
Updated: May 3, 2026

Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet
Published on: November 4, 2015
Pulmonary venoocclusive disease in childhood
Cornelia Woerner1, Ernest Cutz2, Shi-Joon Yoo3
1Department of Pediatrics, Division of Cardiology, University of Toronto, Hospital for Sick Children, Toronto, ON, Canada.
Insights
Pulmonary venoocclusive disease (PVOD) in children is rare and deadly, with a median survival of 14 months post-diagnosis. Early lung transplantation is crucial for survival in pediatric PVOD patients.
Area of Science:
- Pediatric Pulmonology
- Rare Diseases
- Medical Diagnostics
Background:
- Pulmonary venoocclusive disease (PVOD) is a rare cause of pulmonary hypertension (PH), affecting 5-10% of PH patients.
- PVOD's incidence, prevalence, and causes in children are poorly understood.
- Limited treatment options contribute to high mortality rates in pediatric PVOD.
Purpose of the Study:
- To summarize symptoms, associated factors, treatments, and outcomes of pediatric patients with confirmed PVOD.
- To highlight the diagnostic challenges and prognostic factors in pediatric PVOD.
Main Methods:
- Retrospective analysis of nine pediatric patients (1985-2011) with histologically confirmed PVOD.
- Review of patient symptoms, diagnostic timelines, imaging (CT scans), treatments, and survival data.
Main Results:
- PVOD diagnosed at a mean age of 14.3 years, with symptoms like shortness of breath preceding diagnosis by ~21 months.
- Mean survival post-diagnosis was 14 months; treatments included oxygen, diuretics, warfarin, and vasodilators.
- Lung transplantation was pursued in four patients, with one long-term survivor. Eight patients died.
Conclusions:
- PVOD is a critical differential diagnosis for pediatric pulmonary hypertension.
- CT scans aid in identifying lung abnormalities, but lung biopsy is definitive for PVOD diagnosis.
- Early lung transplantation is vital for improving survival in pediatric PVOD, given the short mean survival time.
Background:
Pulmonary venoocclusive disease (PVOD) is a rare lung disease, diagnosed in 5% to 10% of patients with pulmonary hypertension (PH). The incidence, prevalence, and etiology of PVOD in children are not well defined. The mortality remains high, related, at least partly, to the limited treatment options.
Methods:
This retrospective analysis (1985-2011) summarizes symptoms, associated factors, treatment, and outcomes of nine pediatric patients (five girls, four boys) with histologic confirmation of PVOD.
Results:
PH was diagnosed at a mean age of 13.5 years (range, 8-16 years), followed by the definitive diagnosis of PVOD at a mean age of 14.3 years (range, 10-16 years). Symptoms such as decreased exercise tolerance (n = 6) and/or shortness of breath (n = 9) preceded the diagnosis by 21 months on average; the mean survival time after diagnosis was 14 months (range, 0-47 months). CT scans of the lungs showed typical radiologic features. Treatment included supplemental home oxygen (n = 5), diuretics (n = 9), warfarin (n = 4), and pulmonary vasodilators (n = 4). Four children were listed for lung transplantation, and three have undergone transplantation. Eight patients died, including two after lung transplantation. One patient with lung transplant survived with good quality of life.
Conclusions:
PVOD is an important differential diagnosis for pediatric patients with PH. CT scanning is a valuable tool to image lung abnormalities; the definitive diagnosis can only be made by examination of lung biopsy specimens, which subjects the patient to additional risk. Early listing for lung transplantation is essential, as the mean survival time is only 14 months.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Pulmonary Embolism I: Introduction
Pulmonary Embolism I: Introduction
Other Pulmonary Disorders
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Pulmonary Edema II: Pathophysiology

